Work

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.tps8584

Authors: John M. Varlotto, Zhuoxin Sun, Suresh S. Ramalingam, Heather A. Wakelee, Christine M. Lovly, Kurt R. Oettel, Gregory A. Masters, Nate Pennell

Institutions: Edwards Comprehensive Cancer Center, Winship Cancer Institute, Stanford Cancer Institute, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Gundersen Lutheran Hospital, Cleveland Clinic

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3168469466

Cites:

Cited by: 15

Related to: 10